Skip to main content

ADPKD Risk Stratification and Future eGFR Prediction

Risk stratification data

Clinical Data

Classification Results

Height Adjusted TKV
-
ADPKD Class
-

eGFR Predictions

Current eGFR
-
Future eGFR
-

Interpretation

Enter values to see interpretation

GFR Progression Chart

No Data Available

Enter patient information to see GFR progression prediction

About this Calculator

This calculator is designed to help healthcare providers assess and predict the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD). It combines two essential predictive tools:

  • The Mayo Clinic imaging classification system for ADPKD, which categorizes patients into classes 1A-1E based on height-adjusted total kidney volume (htTKV)
  • A validated eGFR prediction model that estimates future kidney function based on current clinical parameters

How to Use:

  1. Enter the total kidney volume and patient demographics in the left panel
  2. Provide clinical data including serum creatinine in the right panel
  3. Specify the desired prediction timeframe in years
  4. Results will automatically calculate and display below

Mayo Clinic Classification Guide

  • Class 1A: Slowest progression (<1.5% growth/year)
  • Class 1B: Slow progression (1.5-3% growth/year)
  • Class 1C: Intermediate progression (3-4.5% growth/year)
  • Class 1D: Rapid progression (4.5-6% growth/year)
  • Class 1E: Fastest progression (>6% growth/year)

Note: This tool is intended for use by healthcare professionals as part of a comprehensive clinical assessment. Results should be interpreted in conjunction with other clinical findings.

See a problem or have an idea for a tool?
Let us know here!

References

ADPKD Classification and Imaging

  • Mayo Clinic Foundation for Medical Education and Research (MFMER). "Classification of Typical ADPKD Calculator." Mayo Clinic PKD Center (2015). Available at: https://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754
  • Irazabal, M.V., et al. "Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials." Journal of the American Society of Nephrology 26.1 (2015): 160-172.
  • Chapman, A.B., et al. "Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease." Clinical Journal of the American Society of Nephrology 7.3 (2012): 479-486.

Height-Adjusted Total Kidney Volume

  • Bhutani, H., et al. "A practical guide to imaging and monitoring autosomal dominant polycystic kidney disease." Clinical Journal of the American Society of Nephrology 15.8 (2020): 1208-1217.
  • Grantham, J.J., et al. "Total kidney volume in autosomal dominant polycystic kidney disease: a biomarker of disease progression and therapeutic efficacy." American Journal of Kidney Diseases 72.3 (2018): 389-399.

Clinical Applications

  • Torres, V.E., et al. "Tolvaptan in patients with autosomal dominant polycystic kidney disease." New England Journal of Medicine 367.25 (2012): 2407-2418.
  • Cornec-Le Gall, E., et al. "The PROPKD Score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease." Journal of the American Society of Nephrology 27.3 (2016): 942-951.
ukidneyisup